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Office of Evidence Based Practice – Specific Care Question:
Emergency Contraception for the Adolescent Patient
Specific Care Questions:
In the adolescent female who presents for emergency contraception (EC), does body mass index (BMI) influence choice of
recommended oral EC?
In the adolescent female who presents for EC does the number of hours from unprotected sexual intercourse influence the
choice of recommended oral EC?
Question Originator:
Melissa Miller, MD
Plain Language Summary from The Office of Evidence Based Practice:
Since the last literature synopsis on the efficacy of levonogestrel (LNG, Plan B) and ulipristal (ULI) for EC, two papers are
added to the summary. The first is (Black et al., 2015) the consensus statement of the Society of Obstetricians and
Gynaecologists of Canada (SOGC), and the second is (Kapp et al., 2015), a secondary analysis of the Creinin et al. (2006)
and Glasier et al. (2010) papers.
In the evaluation of the body of evidence on this question, it is apparent that two papers (Creinin et al., 2006; Glasier et al.,
2010) form the core of the evidence. These studies will be referred to as the core papers hereafter. Papers published since the
initial literature review on 10/2014 are secondary analyses of the data from the core papers. Other secondary sources convey
that ULI is believed to be more effective than LNG (U.S. Department of Health & Human Services, 2014).
Body Mass Index
Based on very low quality evidence, for women who have a BMI of > 25 mg/m2, ULI may have greater efficacy to prevent
pregnancy. The recommendation may change when higher-quality evidence becomes available. Although the core studies
have low risk of bias, the secondary analysis is based on an outcome that the core papers did not intend for the original
research. Further research (if performed) that compares the efficacy of different ECs and stratifies randomization by BMI is
likely to have an important influence on our confidence in the estimate of the effect and is likely to change the estimate of the
effect.
Summary of guidelines
SOGC (Black et al., 2015) states the use of EC should be available to all women seeking it, without regard to BMI, and for
women with a BMI > 25 kg/m2 ULI should be the first choice, if available and affordable.
American Academy of Pediatrics (AAP) (Braverman et al. 2014) states ULI may be used over LNG in adolescents with a body
weight of > 165 pounds based on the Glasier (2010) study, highlighted below.
The Centers for Disease Control and Prevention (CDC, 2013), the European Medicines Agency (EU, 2014), and the Clinical
Effectiveness Unit of the Royal College Faculty of Sexual and Reproductive Healthcare (FSRH, 2012) agree that there is not
enough evidence to use body mass index (BMI reported in kg/m2) as a criteria when choosing between levonogestrel and
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ulipristal for EC.
Primary research papers
Creinin et al. (2006) study was a double-blinded non-inferiority trial. The goal of this trial was to show that ULI was as
efficacious as LNG for EC (see Figure 2). This goal was met. Glaisier, et al. (2010) study was also a double-blinded noninferiority trial. It compared ULI versus LNG up to 120 hours after unprotected sexual intercourse. The goal was to show that
ULI was as efficacious as LNG for EC (see Figure 2). A secondary data meta-analysis is reported in this paper. The authors
combined the data from Creinin et al. (2006) with data from the current study and affirmed with a larger study population that
ULI is not inferior to LNG as an EC (OR = 0.75, 95% CI 0.45, 1.24). The BMI comparison was not reported in the non-inferiority
studies.
Secondary research papers
Glasier et al., (2011) performed a secondary data analysis from the core randomized controlled trials where risk factors of EC
failure were identified. Three factors were found to have a statistically significant effect on the risk of pregnancy: (a) BMI
(kg/m2), (b) conception probability (defined as the period within five days prior to ovulation to 1 day after ovulation), and (c)
further sexual intercourse. However, when participants were stratified by body weight (a) normal or underweight (BMI < 25
kg/m2), (b) overweight (BMI >/= 25 and <30 kg/m2), and (c) obese (BMI >/= 30 kg.m2) statistically significant differences were
not found between body weight groups. However, for the total effect in this analysis, ULI performed significantly better than
LNG (see Figure 3).
Kapp, et al. (2015) performed a secondary data analysis from the core randomized control trials and reported on efficacy of
LNG with the comparison of BMI < 25 kg/m2 versus BMI > 25kg/m2. The authors report that LNG was significantly more
efficacious in preventing pregnancy in women with a BMI <25 kg/m2 (OR= 0.35, 95% CI 0.18, 0.67) than those with a BMI > 25
kg/m2 (see Figure 5).

Although the core studies have low risk of bias, the secondary research papers Glasier et al. (2011) and Kapp et al.(2015)
have biases. The evidence is downgraded for four reasons:

1. The secondary analyses address BMI and EC success or failure in women with BMI > 25 kg/m2. A sample size
calculation is not provided to perform this analysis.
2. There were a low number of treatment failure events (i.e., pregnancy) in the overweight and obese groups. A low
number of events decreases the precision of the findings.
3. It is difficult to repeat the meta-analyses for confirmation. In the core reports, the number of subjects in the efficacy
evaluable populations is 3448 and in the Glasier et al. (2011), secondary analysis the number of subjects is 3445. In
addition, the numbers of treatment failures vary among the reports. The core studies report a sum of 57 treatment
failures, while Glasier et al. (2011) reports 60 treatment failures, a difference of 5%.
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4. Note that the secondary research papers (Glasier, 2011;Kapp, 2015) are prepared by the primary study sponsor (HRA
Pharma), and reporting bias is unclear.
Time to Treatment with ECs
Based on very low quality evidence, the Office of Evidence Based Practice recommends to use either LNG or ULI within the
first 72 hours after unprotected sexual intercourse. Based on very low quality evidence the Office of Evidence Based Practice
makes a conditional recommendation to use ULI for EC in the patient who presents between > 72 and < 120 hours after
unprotected sexual intercourse.
Since the last literature synopsis was performed in October 2014 on the efficacy of levonogestrel (LNG, Plan B) and ulipristal
(ULI, Ella) for EC, no new research was identified that addressed the time to treatment with ECs. The CDC (2013) states that
ECs should be taken as soon as possible within five days of unprotected sexual intercourse, and that ULI and LNG have
similar effectiveness when taken within three days of unprotected coitus. The CDC (2013) continues to state that ULI has been
shown to be more effective three to five days after unprotected sexual intercourse. The AAP Policy Statement concurs with the
CDC (2013) findings and states that ULI may have greater effectiveness at the end of the five day window (Braverman et al.,
2014). The SOGC guideline (Black et al., 2015) also agrees with the CDC’s (2013) statement.
For the “time to treatment with ECs” question, the evidence is found to be very low quality. Although the methods of the
included studies are strong (see Figure 3), the evidence is downgraded for two reasons:

1. There is low number of events in the treatment groups. As seen in Figure 4, for the subgroups at 73-96 hours and 97120 hours, there were a total of three pregnancies reported (low number of events decreases the precision of the
findings).
2. The assessment of reporting bias is unclear; Glasier et al., (2010), there is high level of involvement of the study
sponsor (HRA Pharma),
Overall, there was no difference in treatment failure (pregnancy) between the group treated with ULI and the group treated with
LNG, OR = 0.63, 95% CI [0.37, 1.07], (see Figure 4). The sub-group analysis for time to treatment indicates that for time to
treatment of 0-24 hours and 25-48 hours, there is no difference in EC failure between the two medications. For 49-72 hours to
treatment, ULI has significantly less treatment failure, OR= 0.36, 95% CI [0.13, 0.99]. For times to treatment > 72 hours, data
from ULI is unavailable (see Figure 4).
EBP Scholar’s Responsible for Analyzing the Literature:
Teresa Bontrager, RN, CPEN, BSME
Jarrod Dusin, MS, RD, LD, CNSC
Andrea Melanson, OTD, OTR/L
EBP Team Member Responsible for Reviewing, Synthesizing, and Developing this Literature:
Nancy H Allen, MS, MLS, RD, LD, CNSC
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Search Strategy and Results:
Ovid Search Strategy: Levonogestrel/[Administration & Dosage, Adverse Effects, Contraindications, Pharmacokinetics,
Pharmacology, Therapeutic Use, Standards] AND ulipristal AND (Body Mass Index/ OR Obesity/]
PubMed October 2014
Search Strategy: ("Levonorgestrel"[Mesh] OR levonorgestrel OR lgn OR "plan b") AND ("ulipristal
acetate"[Supplementary Concept] OR "ulipristal"[Supplementary Concept] OR ulipristal OR CDB-2914 OR upa OR
ella) AND (bmi OR "body mass index" OR "Body Mass Index"[Mesh] OR obes* OR overweight OR "Obesity"[Mesh]
OR "Overweight"[Mesh] OR bodyweight)
Filters: English, published within the last 5 years
PubMed 2014 – February 2016
("Contraception, Postcoital"[Mesh] OR "Contraceptives, Postcoital"[Mesh] OR ((contracept* OR "birth control") AND
(postcoital OR emergency)) OR "Levonorgestrel"[Mesh] OR levonorgestrel OR lgn OR "plan b" OR "ulipristal
acetate"[Supplementary Concept] OR "ulipristal"[Supplementary Concept] OR ulipristal OR CDB-2914 OR upa OR ella)
AND (bmi OR "body mass index" OR "Body Mass Index"[Mesh] OR obes* OR overweight OR "Obesity"[Mesh] OR
"Overweight"[Mesh] OR bodyweight OR "body weight") AND ((systematic[sb] OR Meta-Analysis[ptyp] OR Randomized
Controlled Trial[ptyp] OR "Cohort Studies"[Mesh]) AND ("2014/07/01"[PDat] : "3000/12/31"[PDat]) AND English[lang])

TRIP database, Google Scholar, National Guidelines Clearinghouse, Dynamed, UptoDate, and Clinicaltrials.gov Feb 2016
using the keywords ulipristal, levonorgestrel, BMI, overweight, and obes*.
Ovid

February 2016 (Contraeption, Postcoital/ or Contraceptives, Postcoital/ or ((contracept*.mp. or birth control.mp.) and
(emergency.mp. or postcoital.mp.)) or Levonorgestrel/[Administragion & Dosage, Adverse Effects, Contraindications,
Pharmacokinetics, Pharmacology, Standards, Therapeutic Use] or levonogestrel.mp. or lgn.mp. or plan b.mp. or
ulipristal.mp. or upa.mp. or ella.mp.) and (Body Mass Index/ or body mass index.mp. or bmi.mp. or Body Weight/ or
body weight.mp. or bodyweight.mp. or Obesity/ or obes*.mp. or Overweight/ or overweight.mp.)

The literature searches were repeated February 25 2016.
Studies included in this review:
Glasier et al., 2011
Glasier et al., 2010
Creinin et al., 2006
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Kapp et al., 2015
Guidelines and Evidence Reports included in this review:
Black et al., 2015
CDC, 2013
EU, 2014
FSRH, 2012
Method Used for Appraisal and Synthesis:
To answer the questions, (1) does BMI play a role when choosing EC and (2) does time from unprotected sexual intercourse
play a role when choosing EC, OVID, PubMed and the TRIP database, Google Scholar, National Guidelines Clearinghouse,
DynaMed, UptoDate and Clinicaltrials.gov were searched. Searches were performed by a medical librarian and search
strategies are available . Twenty-four articles were identified, and five were chosen for this review. There were two major
reasons for excluding articles (a) they were narrative reviews, and (b) they did not answer the questions. The included articles
are Creinin et al. (2006); Glasier et al. (2011); Glasier et al. (2010); Kapp et al. (2015) The included guidelines and evidence
reports are ACOG, (2010); FSRH, (2012); CDC, (2013); Black et al. (2015).
After studies were selected for review they were verified by the Evidence Based Practice Scholars (EBPS) at Children’s Mercy,
Kansas City. The EBPS, nursing and allied health professionals, who are trained to use the Cochrane Collaborative computer
program, Review Manager (RevMan 5.3), collected the following information from the selected studies:




Article identification information (citation)
Study characteristics (participant description, treatment (medication, dose, frequency), control, primary and secondary
outcomes
 Assessment of potential biases – Primary research studies were assessed for selection, performance, detection,
attrition, and reporting biases.
 Data tables were created to report the results for the primary and secondary outcomes.
The studies that were not RCTs were assessed for the following:





The chance of finding significance when multiple statistical tests are performed on the same data
Ability to repeat the meta-analysis
How potential confounding factors, such as inclusion and exclusion criteria and number of subjects who were exempt
from the analysis

The work of the EBPS was independently validated by a member of the Office of Evidence Based Practice (NHA). If data for
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more than one study was available for the primary or secondary outcomes, estimate of effects were calculated as odds ratios
(OR), with 95% confidence intervals (CIs). We did not contact trial authors for missing data. Three EBPS read the selected
guidelines and scored them using the AGREE II tool (Brouwers et al., 2010). Scores were collated by a member of the Office
of Evidence Based Practice (NHA).
Updated 8/27/2014, 8/28/2014 9/5/2014, 9/18/2014 3/21/2016, 2/16/2016
Table 1
Methods and Risk of Biases Assessments
Creinin 2006
Methods
Participants

RCT, double-blinded non inferiority trial
Setting: a consortium of family practice clinics in the Los Angeles, CA area and five university based
clinical research centers
Randomized: 1672 women age 18+ seeking emergency contraception within 72 hours of unprotected
intercourse
Treatment group (CDB-2914): N=832
Control group (levonorgestrel): N=840
Completed: intent-to-treat population: 1549 (subgroups, broken down into time after unprotected
intercourse: 0-24 hours, 24-48 hours, 48-72 hours)
Treatment group (CDB-2914): N=775 (subgroups N= 273, 268, 234 depending upon elapsed time
after intercourse)
Control group (levonorgestrel) N=774 (subgroups N=263, 298, 213 depending upon elapsed time
after intercourse)
Inclusion Criteria: Healthy women age 18+ not using hormonal contraception who requested
emergency contraception within 72hours after unprotected intercourse, who had a recent history of
regular menstrual cycles and at least one normal menstrual cycle after delivery, abortion, or
discontinuation of hormonal contraceptive.
Exclusion Criteria: women who were pregnant or breastfeeding at time of screening or within 2
months before screening, using an intrauterine device or sterilization as a contraceptive method,
uncertain about date of LMP, nausea or vomiting at time of screening or 2 weeks prior to screening,
using oral glucocorticosteroid replacement therapy, or currently enrolled in another investigational
trial.
Power analysis: done, study goal was to enroll 770 subjects in each group. Numbers were increased
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to 811 to allow for anticipated participants lost to follow-up.
Treatment group: 50mg CDB-2914 + placebo 12 hours later
Control group: 0.75 levonorgestrel x 2, taken 12 hours apart
Occurrence of pregnancy after taking medication (data for 0-24 hours after intercourse, 24-48 hours,
48-72 hours) adverse effects, menstrual cycle length after treatment
"Final model retained site and body mass index as covariates", no information on BMI is listed in this
article.

Interventions
Outcomes
Notes

Risk of Bias Table
Bias
Random sequence
generation (selection bias)
Allocation concealment
(selection bias)
Blinding of participants and
personnel (performance
bias)
Blinding of outcome
assessment (detection bias)
Incomplete outcome data
(attrition bias)
Selective reporting (reporting
bias)
Other bias
Glasier 2011
Methods
Participants
Interventions
Outcomes

Scholars'
judgment
Low risk
Low risk
Low risk

Unclear risk
Low risk
High risk
Unclear risk

Support for judgment
RCT
Study/control drug was supplied in sequentially numbered sealed packages containing
two opaque capsules, packages were identical
Participants and personnel were both blinded to study/control drug. Provisions made to
packaging to ensure that if blinding was broken that tampering would be evident.
Patients knew after study if they were pregnant or not, outcome data for adverse effects
and cycle length were given in percentages, not actual numbers
Number of patients in both groups remained above number required by power analysis.
Data from the efficacy- evaluable population is reported, not all who were randomized.
This study reports that the "final model retained site and body mass index as covariates"
but this is never reported in the actual article.
Weight and height measured

A secondary analysis of a systematic review meta-analysis
Included studies are Creinin 2006 & Glasier 2010
Performed a sub analysis based on BMI Groups: normal weight BMI < 25 kg/m2 ; Overweight BMI 2529.9 kg/m2; obese BMI >/= 30 kg/m2
number of pregnancies
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Glasier 2010
Methods
Participants

RCT, meta-analysis
Setting: 35 family planning clinics across the United Kingdom, Ireland, and USA.
Randomized: 2221 eligible women enrolled and randomized, 1104 assigned to ulipristal acetate and
1117 assigned to levonorgestrel
Age: 24.5 ±6.1years for ulipristal acetate and 24.9±6.5 years for levonorgestrel
Completed: 2133 completed the study: 48 lost to follow-up for ulipristal acetate and 20 lost to follow-up
for levonorgestrel
Gender: all participants were female. 1696 women's data were used for final analysis that reviewed
women who had emergency contraception within 72 hours after unprotected sex and were 35 years of
age or younger.
Inclusion criteria: Women with regular menstrual cycles (24-35 days) seeking emergency
contraception within 120 hours of unprotected sexual intercourse.
Exclusion criteria: Women who were pregnant, breastfeeding, sterilized, fitted with an intrauterine
device, taking hormonal contraception, or whose partners were sterilized were excluded.
Power analysis: 1654 women would be needed to reach at least 85% power to show non-inferiority of
ulipristal acetate versus levonorgestrel when taken within 72hours of sexual intercourse. Taking into
account additional women to be enrolled between 72 hours and 120 hours, and an anticipated rate of
loss to follow-up of 10%, we planned to enroll 2044 women.
Intervention: Enrolled women were randomly assigned to receive ulipristal acetate 30mg or
levonorgestrel 1.5mg given orally. The randomization schedule was stratified by site and time from
unprotected sexual intercourse to treatment (within 72 hours and 72-120 hours) with a block size of
four.
Outcomes: EC failure at 0-24 hours, 25-48 hours, 49-72 hours, 73-96 hours and 97-120 hours

Interventions

Outcomes
Notes
Risk of Bias Table
Bias
Random sequence
generation (selection bias)
Allocation concealment
(selection bias)
Blinding of participants and

Scholars’
judgment
Low risk
Low risk
Low risk

Support for judgment
Block randomization was stratified by center and time from unprotected sexual
intercourse to treatment.
Allocation concealment was completed by identical opaque boxes labeled with a unique
treatment number.
Blinding of participants was ensured but investigators were not; this does not appear to
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personnel (performance
bias)
Blinding of outcome
Low risk
assessment (detection bias)
Incomplete outcome data
Low risk
(attrition bias)
Selective reporting (reporting Low risk
bias)
Other bias

High risk

influence outcome.
Outcome assessment was not blinded by investigators but does not appear to impact
outcome analysis
No missing data found for outcomes. Data from the efficacy- evaluable population is
reported, not all who were randomized.
Study protocol is available and all of study's pre-specified data were included. However,
they add data from a previous study in which the ULI was formulated as a capsule, and
in this study they use a tablet with ULI that has been micronized.
The sponsor of the study was involved in study design, data collection, data analysis,
data interpretation, and writing of the report. The corresponding author had full access to
all the data in the study and had final responsibility for the decision to submit for
publication.
Weight and height were self-reported.

Kapp 2015
Methods
Participants
Interventions
Outcomes
Notes

A secondary analysis of a systematic review meta-analysis
Included studies are Creinin 2006 & Glasier 2010
Performed a sub analysis based on BMI Groups: normal weight BMI < 25 kg/m2 ; Overweight BMI 2529.9 kg/m2; obese BMI >/= 30 kg/m2 on LNG only
number of pregnancies

By combining the two studies, the power analysis from Creinin 2006 and Glasier 2010 was
met for the LNG only comparison.
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Figure 1. Risk of Bias Summary
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ULI
Study or Subgroup

LNG

Odds Ratio

Events Total Events Total Weight

M-H, Fixed, 95% CI

Creinin 2006

12

792

14

786

34.9%

0.85 [0.39, 1.85]

Glaiser 2010

15

941

25

852

65.1%

0.54 [0.28, 1.02]

1638 100.0%

0.64 [0.39, 1.06]

Total (95% CI)
Total events

1733
27

M-H, Fixed, 95% CI

39

Heterogeneity: Chi² = 0.79, df = 1 (P = 0.37); I² = 0%
Test for overall effect: Z = 1.74 (P = 0.08)

Odds Ratio

0.01

0.1

1

10

100

ULI LNG

Figure 2. ULI vs. LNG (Modified ITT or Per Protocol analysis), Outcome: Treatment failure (lower is better) Overall
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Figure 3. Ulipristal vs. Levonorgestrel, Outcome: Treatment failure (lower is better) by BMI
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Figure 4. Ulipristal vs. levonogestrel, Outcome EC failure (pregnancy) by time to treatment
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Figure 5. BMI < 25 kg/m2 vs. BMI > 25 kg/m2, Outcome: Treatment failure when treated with LNG alone (lower is better)
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